Tuberculosis—resistance, funding, and drugs - ScienceDirect

The Lancet Infectious Diseases

Volume 10, Issue 5, May 2010, Pages 297-298

The Lancet Infectious Diseases

https://doi.org/10.1016/S1473-3099(10)70083-9 Get rights and content

References (0)

Cited by (8)

Establishment of an indirect ELISA for Mycobacterium tuberculosis MTB39A protein antibody
2023, Applied Microbiology and Biotechnology
Occurrence rate of rifampicin-resistant Mycobacterium tuberculosis in patients attending chest clinics in selected hospitals in Akure metropolis
2022, Microbes and Infectious Diseases
Determinants of multi-drug resistant tuberculosis in four treatment centers of Eastern Amhara, Ethiopia: A case-control study
2021, Journal of Infection in Developing Countries
Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria
2018, African Health Sciences
Multidrug-resistant tuberculosis and risk factors associated with its development: A retrospective study
2015, Journal of Infection in Developing Countries
Drug resistance pattern and associated risk factors of tuberculosis patients in the central province of iran
2013, Caspian Journal of Internal Medicine

View all citing articles on Scopus

Copyright © 2010 Published by Elsevier Ltd. All rights reserved.